{
 "id": "amyloidosis",
 "name": "Amyloidosis",
 "aliases": [],
 "acronyms": [],
 "bodySystem": "endocrine",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 2
 },
 "funds": [
  {
   "fund": "Amyloidosis",
   "organization": "HealthWell Foundation",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "fund": "Amyloidosis",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 5500,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "Tafamidis",
   "pages": [
    {
     "brand": "Vyndamax",
     "url": "https://omnirx.org/medicines/vyndamax"
    }
   ],
   "labelSentence": "VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%221b4121ee-a733-4456-a917-be2603477839%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Pfizer RxPathways (Pfizer Patient Assistance Program)",
     "url": "https://omnirx.org/assistance/pfizer-rxpathways",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "products remaining within Pfizer PAP as of January 1, 2026",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Tafamidis Meglumine",
   "pages": [
    {
     "brand": "Vyndamax",
     "url": "https://omnirx.org/medicines/vyndamax"
    }
   ],
   "labelSentence": "VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%221b4121ee-a733-4456-a917-be2603477839%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Pfizer RxPathways (Pfizer Patient Assistance Program)",
     "url": "https://omnirx.org/assistance/pfizer-rxpathways",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "products remaining within Pfizer PAP as of January 1, 2026",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Vutrisiran Sodium",
   "pages": [
    {
     "brand": "Amvuttra",
     "url": "https://omnirx.org/medicines/amvuttra"
    }
   ],
   "labelSentence": "... the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%228db0facb-81b6-4006-9239-27dc6409c5d3%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}